We work Hard to get you posted with latest updates

http://We%20work%20Hard%20to%20get%20you%20posted%20with%20latest%20updates

Spend time learning about the different aspects of that topic from experts in the field.

AI drug discovery AI healthcare artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy

Unwrap our new Directory

http://Unwrap%20our%20new%20Directory

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Precigen

Advertisement

cGxPJobs Banner

FDA Approves Precigen’s PAPZIMEOS, First Immunotherapy for Recurrent Respiratory Papillomatosis

August 19, 2025 — Germantown, MD – Precigen, Inc. (NASDAQ: PGEN) today announced that the U.S. Food and Drug...

By cGxPwire Editor
August 19, 2025

Read More

Advertisement

cGxPJobs

Recent Posts

01

.Clinical

Delphi Diagnostics Validates EAI for Paclitaxel Benefit
June 23, 2026
02

.Clinical

Hamlet BioPharma Advances Alpha1H into Phase 3 Trial
June 23, 2026
03

MedTech

Draeger Receives FDA Clearance for Evita V800 Upgrade
June 23, 2026
04

.Clinical

Phanes Completes Phase 2 Enrollment for Spevatamig in PDAC
June 23, 2026
05

.Clinical

Hamlet BioPharma Expands Alpha1H Trial for Bladder Cancer
June 23, 2026

Advertisement

Copyright © 2026 cGxP.wire | Made by 3styler

Directory

Home
Pharma
Bio-Pharma
MedTech
Veterinary
Cosmetics
Food
.Clinical
.Tech
.edu
.gov
M&A
.VC

Start typing and press Enter to search

Loading Comments...

Write a Comment...

Email (Required)

Name (Required)

Website